500859-96-1

Basic information

• Product Name: Benzaldehyde, 4-hydroxy-3-(4-morpholinylmethyl)-
• CAS NO: 500859-96-1
• Molecular Formula: C12H15NO3
• Molecular Weight: 221.256
• Mol File: 500859-96-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzaldehyde, 4-hydroxy-3-(4-morpholinylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzaldehyde, 4-hydroxy-3-(4-morpholinylmethyl)-(500859-96-1)
• EPA Substance Registry System: Benzaldehyde, 4-hydroxy-3-(4-morpholinylmethyl)-(500859-96-1)

Safety Data

• Hazardous Substances Data: 500859-96-1(Hazardous Substances Data)

Upstream product

• 123-08-0 4-hydroxy-benzaldehyde 
• 110-91-8 morpholine 
• 50-00-0 formaldehyd 

Downstream Products

• 1197291-78-3 4-formyl-2-(morpholinomethyl)phenyl trifluoromethanesulfonate 
• 1197291-84-1 tert-butyl (1s,4s)-4-(2-(4'-(((3S,5R)-3,5-dimethylpiperazin-1-yl)methyl)-2'-(morpholinomethyl)biphenyl-3-yloxy)-5-fluoronicotinamido)cyclohexylcarbamate 
• 1628847-80-2 N-((1s,4s)-4-(2-(4'-(((3S,5R)-3,5-dimethylpiperazin-1-yl)methyl)-2'-(morpholinomethyl)biphenyl-3-yloxy)-5-fluoronicotinamido)cyclohexyl)-4-methylthiazole-2-carboxamide trifluoroacetic acid salt 
• 1197291-79-4 tert-butyl (1s,4s)-4-(5-fluoro-2-(4'-formyl-2'-(morpholinomethyl)biphenyl-3-yloxy)nicotinamido)cyclohexylcarbamate 

Relevant articles and documents

One-Pot Three-Component Synthesis of 2,4,5-Triaryl-1H-imidazoles Using Mn2+Complex of [7-Hydroxy-4-methyl-8-coumarinyl] Glycine as a Heterogeneous Catalyst

A highly efficient and simple synthesis of 2,4,5-trisubstituted imidazoles has been developed using highly reusable support‐free Mn2+complex of [7-hydroxy-4-methyl-8-coumarinyl] glycine as a heterogeneous catalyst via a one-pot three-component reaction of benzil, aldehydes and ammonium acetate as a nitrogen source. Moreover, this catalyst was characterized by various techniques such as field emission scanning electron microscope (FE-SEM), energy dispersive X-ray spectroscopy (EDX), FT-IR spectroscopy, powder X-ray diffraction (XRD), inductively coupled plasma (ICP) and thermal gravimetric analysis (TGA). Also, the catalyst is stable and could be reused for at least six times without significant loss of activity. Graphic Abstract: [Figure not available: see fulltext.]

Synthesis and in Vitro Anticancer Activity of the First Class of Dual Inhibitors of REV-ERBβ and Autophagy

Autophagy inhibition is emerging as a promising anticancer strategy. We recently reported that the circadian nuclear receptor REV-ERBβ plays an unexpected role in sustaining cancer cell survival when the autophagy flux is compromised. We also identified 4-[[[1-(2-fluorophenyl)cyclopentyl]amino]methyl]-2-[(4-methylpiperazin-1-yl)methyl]phenol, 1 (ARN5187), as a novel dual inhibitor of REV-ERBβ and autophagy. 1 had improved cytotoxicity against BT-474 breast cancer cells compared to chloroquine, a clinically relevant autophagy inhibitor. Here, we present the results of structure-activity studies, based around 1, that disclose the first class of dual inhibitors of REV-ERBβ and autophagy. This study led to identification of 18 and 28, which were more effective REV-ERBβ antagonists than 1 and were more cytotoxic to BT-474. The combination of optimal chemical and structural moieties of these analogs generated 30, which elicited 15-fold greater REV-ERBβ inhibitory and cytotoxic activities compared to 1. Furthermore, 30 induced death in a panel of tumor cell lines at doses 5-50 times lower than an equitoxic amount of chloroquine but did not affect the viability of normal mammary epithelial cells.